Disclosed is the topical pharmaceutical formulation comprising a solution of heparin and 5% to 15% of at least one polyoxyalkylene ester of a hydroxy fatty acid. Preferred polyoxyalkylene ester of a hydroxy fatty acid include a polyglycol ester of polyethylene glycol and 12-hydroxystearic acid (Macrogol 15 hydroxystearate).